Desonide Continues to Thrive as a Treatment for Atopic Dermatitis


DesonideOn June 4, 2013 Aqua Pharmaceuticals announced its acquisition of the brand name foam of Desonide, coined Verdeso, from Stiefel Pharmaceuticals. This announcement was extremely positive for Aqua Pharmaceuticals, as they already hold a thriving lineup of dermatologic products, such as Fluoroplex and Cordran. The addition of Verdeso, a foam formulation of Desonide, has filled a crucial hole in the array of products used to treat atopic dermatitis. With the patent for Verdeso set to expire on December 8, 2019, the time is ripe for research and development of generic products for this easy to use and effective foam treatment.

As an ethanol free treatment for atopic dermatitis, Desonide foam is primarily emollient based. Safe for adults and children three months of age and older, Desonide foam contains a corticosteroid that is considered to be low-potency. Typical treatment for patients utilizing the 0.05% foam form of Desonide involves one to four consecutive weeks of treatment, not to exceed four months of continuous applications without a doctor’s approval. Adverse effects of Desonide foam are uncommon, but as with all forms of corticosteroids side effects may include a slight risk of Cushing’s syndrome, swelling and growth retardation in children. However, the majority of patients dosed with Desonide foam, adults and children alike, experience no adverse side effects. Typical mild complaints from a minority of patients who are dosed with Desonide foam are application site burning or itching and slight headache.

Atopic dermatitis is a type of eczema that occurs most often in children and young adults, but also affects quite a number of adults. This inflammatory and unfortunately chronic skin disorder affects roughly three percent of the total population in the United States. When atopic dermatitis is left untreated this condition often leads to secondary infections. Some cases of atopic dermatitis are hereditary; although environmental factors are thought to contribute greatly to this frustrating skin disorder.

LGM Pharma provides the Desonide TEVA API for compounding in the U.S., as well as the Desonide CAS# 638-94-8 API for drug development and R&D purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.

 

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

 

  • Share: